Red Algae Goes Blue: FDA Greenlights Algae Dye
Published Date: 5/12/2025
Rule
Summary
The FDA is giving a green light to use a new natural blue color called galdieria extract blue, made from red algae, in lots of foods. This change helps food makers add a safe, cool blue shade while following good manufacturing rules. Food companies and consumers can expect this update to roll out soon, with no extra costs flagged.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Food makers cleared to use new blue
The FDA amended color additive rules to allow use of ‘‘galdieria extract blue,’’ made from unicellular red algae (Galdieria sulphuraria), in various food categories at levels consistent with good manufacturing practice (GMP). Food manufacturers who add color to products may now use this ingredient under the FDA rule.
Consumers get new natural blue option
The FDA approved a new natural blue color called ‘‘galdieria extract blue,’’ derived from Galdieria sulphuraria, for use in various food categories at levels consistent with good manufacturing practice (GMP). The summary says consumers can expect this update to roll out soon and that no extra costs were flagged.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-08249 — Listing of Color Additives Exempt From Certification; Calcium Phosphate
The FDA is giving a green light to use calcium phosphate as a color additive in ready-to-eat chicken, white candy melts, doughnut sugar, and coated candy sugar. This change helps food makers add safe color to these treats without extra costs or delays. If you’re in the food biz, get ready to brighten up your products with this new option!
Next: 2025-08268 — Fisheries of the Northeastern United States; Atlantic Spiny Dogfish Fishery; 2025 Specifications
Fishermen who catch Atlantic spiny dogfish will follow new rules in 2025 to keep the fish population healthy and fishing fair. These rules set how many dogfish can be caught to avoid overfishing while making sure the fishery stays productive. The changes kick in next year and help balance nature and business for everyone involved.